Medpace Holdings, Inc. (MEDP) stock
MEDPNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 22, 2026Score 14/3042% above fair value
$653.09+4.89 (+0.75%)
Close on Nov 17, 2026Market cap $18.27BP/E 36.2Yield –
Medpace EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Medpace's EPS for the twelve months ending Sep 30, 2026 was $18.03, up 26.1% year over year. For fiscal 2025 it was $15.28, up 21.0% from the year before. The highest annual figure on record is $15.28 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.28 | +21.0% |
| FY2024 | Dec 31, 2024 | $12.63 | +42.2% |
| FY2023 | Dec 31, 2023 | $8.88 | +22.0% |
| FY2022 | Dec 31, 2022 | $7.28 | +51.4% |
| FY2021 | Dec 31, 2021 | $4.81 | +25.3% |
| FY2020 | Dec 31, 2020 | $3.84 | +43.8% |
| FY2019 | Dec 31, 2019 | $2.67 | +35.5% |
| FY2018 | Dec 31, 2018 | $1.97 | +101.0% |
| FY2017 | Dec 31, 2017 | $0.98 | +164.9% |
| FY2016 | Dec 31, 2016 | $0.37 | – |
| FY2015 | Dec 31, 2015 | -$0.28 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.84 | +25.4% |
| Q2 FY2026 | Jun 30, 2026 | $4.25 | +37.1% |
| Q1 FY2026 | Mar 31, 2026 | $4.28 | +16.6% |
| Q4 FY2025 | Dec 31, 2025 | $4.66 | +27.0% |
| Q3 FY2025 | Sep 30, 2025 | $3.86 | +28.2% |
| Q2 FY2025 | Jun 30, 2025 | $3.10 | +12.7% |
| Q1 FY2025 | Mar 31, 2025 | $3.67 | +14.7% |
| Q4 FY2024 | Dec 31, 2024 | $3.67 | +49.2% |
| Q3 FY2024 | Sep 30, 2024 | $3.01 | +35.6% |
| Q2 FY2024 | Jun 30, 2024 | $2.75 | +42.5% |
| Q1 FY2024 | Mar 31, 2024 | $3.20 | +41.0% |
| Q4 FY2023 | Dec 31, 2023 | $2.46 | +16.0% |
| Q3 FY2023 | Sep 30, 2023 | $2.22 | +8.3% |
| Q2 FY2023 | Jun 30, 2023 | $1.93 | +32.2% |
| Q1 FY2023 | Mar 31, 2023 | $2.27 | +34.3% |
| Q4 FY2022 | Dec 31, 2022 | $2.12 | +60.6% |
| Q3 FY2022 | Sep 30, 2022 | $2.05 | +58.9% |
| Q2 FY2022 | Jun 30, 2022 | $1.46 | +37.7% |
| Q1 FY2022 | Mar 31, 2022 | $1.69 | +48.2% |
| Q4 FY2021 | Dec 31, 2021 | $1.32 | -1.5% |
| Q3 FY2021 | Sep 30, 2021 | $1.29 | +18.3% |
| Q2 FY2021 | Jun 30, 2021 | $1.06 | +65.6% |
| Q1 FY2021 | Mar 31, 2021 | $1.14 | +50.0% |
| Q4 FY2020 | Dec 31, 2020 | $1.34 | +71.8% |
| Q3 FY2020 | Sep 30, 2020 | $1.09 | +73.0% |
| Q2 FY2020 | Jun 30, 2020 | $0.64 | -12.3% |
| Q1 FY2020 | Mar 31, 2020 | $0.76 | +49.0% |
| Q4 FY2019 | Dec 31, 2019 | $0.78 | +27.9% |
| Q3 FY2019 | Sep 30, 2019 | $0.63 | +21.2% |
| Q2 FY2019 | Jun 30, 2019 | $0.73 | +62.2% |
| Q1 FY2019 | Mar 31, 2019 | $0.51 | +27.5% |
| Q4 FY2018 | Dec 31, 2018 | $0.61 | +103.3% |
| Q3 FY2018 | Sep 30, 2018 | $0.52 | +108.0% |
| Q2 FY2018 | Jun 30, 2018 | $0.45 | +95.7% |
| Q1 FY2018 | Mar 31, 2018 | $0.40 | +100.0% |
| Q4 FY2017 | Dec 31, 2017 | $0.30 | – |
| Q3 FY2017 | Sep 30, 2017 | $0.25 | – |
| Q2 FY2017 | Jun 30, 2017 | $0.23 | – |
| Q1 FY2017 | Mar 31, 2017 | $0.20 | – |
| Q4 FY2016 | Dec 31, 2016 | $0.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?